Detalles de la búsqueda
1.
The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides.
Cancer Immunol Immunother
; 71(4): 919-932, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34519839
2.
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Br J Cancer
; 123(11): 1590-1598, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32913286
3.
Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.
Future Oncol
; 15(9): 1021-1034, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30757910
4.
Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA.
Future Oncol
; 14(25): 2627-2642, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29911900
5.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Blood
; 124(7): 1047-55, 2014 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-24904120
6.
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood
; 121(18): 3703-8, 2013 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-23502220
7.
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Blood
; 117(4): 1141-5, 2011 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-21098399
8.
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
Oncotarget
; 14: 57-70, 2023 01 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36702329
9.
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.
Blood
; 114(15): 3299-308, 2009 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-19625708
10.
Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides.
Cancers (Basel)
; 13(23)2021 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34885092
11.
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Lancet Haematol
; 8(11): e808-e817, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34627593
12.
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Clin Cancer Res
; 27(8): 2190-2199, 2021 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33451977
13.
A der(8)t(8;11) chromosome in the Karpas-620 myeloma cell line expresses only cyclin D1: yet both cyclin D1 and MYC are repositioned in close proximity to the 3'IGH enhancer.
DNA Repair (Amst)
; 8(3): 330-5, 2009 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19064000
14.
Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
Clin Pharmacol Drug Dev
; 9(7): 876-888, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32488989
15.
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.
Clin Cancer Res
; 26(14): 3546-3556, 2020 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32327472
16.
Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
J Comp Eff Res
; 8(6): 393-402, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30855175
17.
Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma.
Oncotarget
; 10(35): 3285-3293, 2019 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31143374
18.
Characterizing the Sources of Pharmacokinetic Variability for TAK-117 (Serabelisib), an Investigational Phosphoinositide 3-Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy.
Clin Pharmacol Drug Dev
; 8(5): 637-646, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30168905
19.
Predicting Outcomes in Patients With Diffuse Large B-Cell Lymphoma Treated With Standard of Care.
Cancer Inform
; 18: 1176935119835538, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30906191
20.
Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study.
Clin Lymphoma Myeloma Leuk
; 19(4): e172-e183, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30691994